Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

232
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
232
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

216
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
216
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

204
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
204

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP.

British journal of haematology·2023
Same author

Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.

Annals of hematology·2021
Same author

Complement-mediated thrombotic microangiopathy associated with lupus nephritis.

Blood advances·2018
Same author

Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients.

British journal of haematology·2017

Related Experiment Video

Updated: Aug 4, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

28.8K

Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.

Ilene Ceil Weitz1

  • 1Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA.

Journal of Blood Medicine
|April 5, 2023
PubMed
Summary

Pegcetacoplan, a novel C3 inhibitor, is FDA-approved for Paroxysmal Nocturnal Hemoglobinuria (PNH). This review covers its efficacy, safety, and clinical use in PNH patients.

Keywords:
PNHcomplement inhibitionextravascular hemolysis

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.7K

Related Experiment Videos

Last Updated: Aug 4, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

28.8K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.7K

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare blood disorder.
  • The complement system plays a key role in PNH pathogenesis.
  • Current treatments aim to inhibit complement-mediated hemolysis.

Purpose of the Study:

  • To review the efficacy and safety of Pegcetacoplan for PNH treatment.
  • To discuss clinical considerations for using Pegcetacoplan in PNH patients.

Main Methods:

  • Review of clinical trial data for Pegcetacoplan in PNH.
  • Analysis of safety and efficacy endpoints from published studies.

Main Results:

  • Pegcetacoplan demonstrated significant efficacy in PNH patients.
  • The safety profile of Pegcetacoplan was evaluated in clinical trials.

Conclusions:

  • Pegcetacoplan is an effective and approved therapy for PNH.
  • Considerations for Pegcetacoplan use in PNH management are discussed.